Israel Active

Nefesh B’Nefesh, in cooperation with The Jewish Agency for Israel, hosted the first-ever MedEx events in Australia, for over 100 Jewish doctors in Sydney and Melbourne. It is part of the International Medical Aliyah Program (IMAP), streamlining the process for doctors making Aliyah.

The UK Embassy in Israel has launched the 2nd cohort of the Dangoor Health-Tech Academy, a joint initiative by the UK-Israel Tech Hub and the Dangoor Foundation. The 8-week program connects Israeli health-tech start-ups with the UK healthcare ecosystem, focusing on mental-health innovation.

Researchers from University of Haifa’s Sagol Department of Neurobiology have combined genetics and AI to detect suicidal tendencies in bipolar patients with near-perfect precision, offering a new hope for early intervention. They identified distinctive molecular signatures in high-risk patients.

Researchers at Israel’s Ben-Gurion University and at Israel’s Weizmann Institute have discovered a new subset of T helper cells - CD4-Eomes cells – are prominent in people well over 100 years old. these T helper cells act to clean out the system of senescence cells that accelerate aging.

Detailed article about the magnetic field helmet invented by Yaron Segal and commercialized by Israel’s BrainQ (see previously). It now has the CE mark – which means it’s safe to be sold and used across Europe – and has been approved by Israel’s ministry of health.

Israel spends less than most OECD countries on health, yet it has one of the lowest levels of infant mortality, heart disease mortality, and preventable deaths. Israel’s average life expectancy is 83.8 years – almost a year more than in 2023 and the fourth highest in the OECD.

Downton Abbey creator Lord Julian Fellowes was successfully treated for essential tremor at St. Mary’s Hospital, London with the incisionless focused ultrasound therapy from Israel’s Insightec. He had lost the ability to write by hand due to involuntary shaking.

The new US policy announcement making In Vitro Fertilization (IVF) more accessible is good news for Israel, which has been at the forefront of IVF treatment for decades. It opens up a massive opportunity for medical technology companies, particularly in Israel’s vibrant fem-tech scene.

A new study from the Hebrew University of Jerusalem shows that the auditory cortex, one of the brain’s main sound-processing centers, changes how it operates when we focus on a task. It synchronizes its activity to the rhythm of the task rather than merely reacting to sounds.

Israel’s Immunai has used its immune system AI mapping platform to discover a novel therapeutic target for inflammatory bowel disease (IBD). Immunai has partnered with AstraZeneca who will develop the therapy, which if successful will earn Immunai up to $85 million.